Preview

Колопроктология

Расширенный поиск

ДИАГНОСТИЧЕСКИЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ФЕКАЛЬНОГО КАЛЬПРОТЕКТИНА У ПАЦИЕНТОК С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА В ПЕРИОД БЕРЕМЕННОСТИ (обзор литературы и клинические наблюдения)

https://doi.org/10.33878/2073-7556-2018-0-2-95-101

Полный текст:

Об авторах

Юлия Борисовна Успенская
ФГАОУ ВО Первый МГМУ им. И.М.Сеченова Минздрава России
Россия


С. Ю. Белогубова
ФГАОУ ВО Первый МГМУ им. И.М.Сеченова Минздрава России
Россия


Список литературы

1. Abdul Sultan, A. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England. / A.Abdul Sultan, J.West, L.Ban et al. // Inflamm. Bowel Dis. - 2016. - № 22. - р. 1621-1630.

2. Alibrahim, B. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. / B.Alibrahim, M.I.Aljasser, B.Salh // J. Gastroenterol. Hepatol. - 2015 Apr. - № 29 (3). - р. 157-63.

3. Balint, A. Pregnancy does not affect fecal calprotectin concentration in healthy women. / A.Balint, A.Berényi, K.Farkas et al. // The Turkish Journal of Gastroenterology. - 2017. - № 28 (3). -р. 171-175.

4. Bickelhaupt, S. Crohn’s disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. / S.Bickelhaupt, S.Pazahr, N.Chuck et al. // Neurogastroenterol. Motil. - 2013 Jun. - № 25 (6). -р. 467-73.

5. Bjarnason, I. The Use of Fecal Calprotectin in Inflammatory Bowel Disease. / I.Bjarnason // Gastroenterology & hepatology. - 2017. - № 13 (1). -р. 53.

6. Boschetti, G. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. / G.Boschetti, M.Laidet, D.Moussata et al. // Am. J. Gastroenterol. - 2015. - № 110. -р. 865-872.

7. Committee Opinion. Guidelines for Diagnostic Imaging during Pregnancy. American Washington, DC, USA: College of Obstetricians and Gynecologists. - 2004.

8. Costa, F. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. / F.Costa, M.G.Mumolo, L.Ceccarelli et al. // Gut. - 2005 Mar. - № 54 (3). - р. 364-8.

9. Darr, U. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. / U.Darr, N.Khan // Curr. Treat. Options Gastroenterol. - 2017 Mar. - № 15 (1). - р. 116-125.

10. De Vos, M. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. / M.De Vos, E.J.Louis, J.Jahnsen et al. // Inflamm. Bowel Dis. - 2013. - № 19. - р. 2111-7.

11. De Vos, M. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. / M.De Vos, E.J.Louis, J.Jahnsen et al. // Inflamm. Bowel Dis. - 2013. - р. 19:2111-7.

12. D’Incà, R. Can calprotectin predict relapse risk in inflammatory bowel disease? / R.D’Incà, Dal E.Pont, V.Di Leo // Am. J. Gastroenterol. - 2008 Aug. -№ 103 (8). - р. 2007-14.

13. Fagerhol, M.K. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. / M.K.Fagerhol, I.Dale, T.Andersson // Bull Eur. Physiopathol. Respir. -1980. - № 16 (Suppl). - р. 273-82.

14. Garaa-Sânchez, V. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? / V.Garaa-Sânchez, E.Iglesias-Flores, R.Gonzalez et al. // J. Crohns Colitis. - 2010 Jun. -№ 4 (2). - р. 144-52.

15. Gisbert, J.P. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. / J.P.Gisbert, F.Bermejo, J.L.Perez-Calle et al. // Inflamm. Bowel Dis. - 2009 Aug. - № 15 (8). - р. 11901198.

16. Gomollôn, F. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: Part 1: diagnosis and medical management. / F.Gomollôn, A.Dignass, V.Annese et al. // J. Crohns Colitis. - 2017. - № 11 (1). - р. 3-25.

17. http://ecco-jcc.oxfordjournals.org/content/ eccojc/9/2/107.full.pdf.

18. Johne, B. Functional and clinical aspects of the myelomonocyte protein calprotectin. / B.Johne, M.K.Fagerhol, T.Lyberg et al. // Mol. Pathol. - 1997. -№ 50. - р. 113-23.

19. Jones, J. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. / J.Jones, E.V.Jr.Loftus, R.Panaccione et al. // Clin. Gastroenterol. Hepatol. -2008 Nov. - № 6 (11). - р. 1218-24.

20. Julsgaard, M. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. / M.Julsgaard, C.L.Hvas, R.B.Gearry et al. // Inflamm. Bowel Dis. - 2017 Jul. - № 23 (7). - р. 1240-1246.

21. Kallel, L. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. / L.Kallel, I.Ayadi, S.Matri et al. // Eur. J. Gastroenterol. Hepatol. - 2009 Mar. -№ 22 (3). - р. 340-345.

22. Kostas, A. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. / A.Kostas, S.I.Siakavellas, C.Kosmidis et al. // World J. Gastroenterol. - 2017 Nov 7. - № 23 (41). -р. 7387-7396.

23. Langhorst, J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. / J.Langhorst, S.Elsenbruch, J.Koelzer et al. // Am. J. Gastroenterol. - 2008 Jan. - № 103 (1). -р. 162-9.

24. Lin, J.F. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. / J.F.Lin, J.M.Chen, J.H.Zuo et al. // Inflamm. Bowel Dis. - 2014 Aug. - № 20 (8). - р. 1407-15.

25. Liverani, E. How to predict clinical relapse in inflammatory bowel disease patients. / E.Liverani, E.Scaioli, R.J.Digby et al. // World Journal of Gastroenterology. - 2016. - № 22 (3). - р. 1017-1033.

26. Louis, E. Maintenance ofremission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. / E.Louis, J.Y.Mary, G.Vernier-Massouille et al. // Gastroenterology. - 2012 Jan. - № 142 (1). - р. 63-70. e5; quiz e31.

27. Magro, F. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. / E.Louis, J.Y.Mary, G.Vernier-Massouille et al. // J. Crohns Colitis. - 2017. - № 11. - р. 649-670.

28. McConnell, Ryan A. et al. Pregnancy and the Patient with Inflammatory Bowel Disease. / Ryan A.McConnell, et al. // Gastroenterology Clinics. - 2016. - № 45 (2). - р. 285-301.

29. Molander, P. Does fecal calprotectin predict short-term relapse after stopping TNFa-blocking agents in inflammatory bowel disease patients in deep remission? / P.Molander, M.Farkkila, A.Ristimaki et al. // Journal of Crohn’s & Colitis. - 2015. - № 9 (1). -р. 33-40.

30. Nguyen, G. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. / G.Nguyen, C.Seow, C.Maxwell et al. // Gastroenterology. - 2016 Mar. - № 150 (3). - p. 734757.

31. O’Toole, A. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. / A.O’Toole, O.Nwanne, T.Tomlinson // Digestive diseases and sciences. - 2015. - № 60 (9). - p. 27502761.

32. Roseth, A.G. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. / A.G.Roseth, E.Aadland, J.Jahnsen et al. // Digestion. - 1997. № 58. -p. 176-80.

33. R0seth, A.G. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. / A.G.R0seth, M.K.Fagerhol, E.Aadland et al. // Scand. J. Gastroenterol. - 1992 Sep. - № 27 (9). - p. 793-8.

34. Roseth, A.G. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. / A.G.Roseth, P.N.Schmidt, M.K.Fagerhol // Scand J. Gastroenterol. - 1999. - № 34. - p. 50-4.

35. Schoepfer, A. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. / A.Schoepfer, C.Beglinger, A.Straumann et al. // Inflammatory Bowel Diseases. - 2013. - № 19 (2). - p. 332-341.

36. Schoepfer, A.M. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. / A.M.Schoepfer, C.Beglinger, A.Straumann et al. // Am. J. Gastroenterol. - 2010. - № 105 (1). p. 162-169.

37. Schweistein, H. Serum Chitinase 3-like-1 (CHI3L1) and Fecal Calprotectin Levels for Non-Invasive Disease Activity Assessment in IBD Patients During Pregnancy. / H.Schweistein, T.Adar, S.Shteingart et al. // Gastroenterology. - 2016. - № 150 (4). - S987.

38. Shitrit, A. Limitations in Using Fecal Calprotectin As a Biomarker of IBD Disease Activity During Pregnancy. / A.Shitrit, I.Miznikov, T.Adar et al. // Gastroenterology. - 2015. - № 148 (4). - S-452.

39. Sipponen, T. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. / T.Sipponen, K.L.Kolho // Scand J. Gastroenterol. -2010 Aug. - № 45 (7-8). - p. 872-7.

40. Sipponen, T. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. / T.Sipponen, E.Savilahti, K.L.Kolho et al. // Inflamm. Bowel Dis. - 2008 Jan. - № 14 (1). - p. 40-46.

41. Tibble, J.A. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. / J.A.Tibble, G.Sigthorsson, S.Bridger et al. // Gastroenterology. -2000 Jul. - № 119 (1). - p. 15-22.

42. Van Rheenen, P.F. Fecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. / P.F.Van Rheenen, E.Van de Vÿver, V.Fidler // The BMJ. - 2010. - № 341. -c3369.

43. Vermeire, S. C-reactive protein as a marker for inflammatory bowel disease. / S.Vermeire, A.G.Van, P.Rutgeerts // Inflamm. Bowel Dis. - 2004. - № 10. -p. 661-665.

44. Walkiewicz, D. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. / D.Walkiewicz, S.L.Werlin, D.Fish et al. // Inflamm. Bowel Dis. - 2008 May. - № 14 (5). -p. 669-73.

45. Walsham, N.E. Fecal calprotectin in inflammatory bowel disease. / N.E.Walsham, R.A.Sherwood // Clin. Exp. Gastroenterol. - 2016. - № 9. - p. 21-29.


Для цитирования:


Успенская Ю.Б., Белогубова С.Ю. ДИАГНОСТИЧЕСКИЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ФЕКАЛЬНОГО КАЛЬПРОТЕКТИНА У ПАЦИЕНТОК С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА В ПЕРИОД БЕРЕМЕННОСТИ (обзор литературы и клинические наблюдения). Колопроктология. 2018;(2):95-101. https://doi.org/10.33878/2073-7556-2018-0-2-95-101

For citation:


Uspenskaya Y.B., Belogubova S.J. DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). Koloproktologia. 2018;(2):95-101. (In Russ.) https://doi.org/10.33878/2073-7556-2018-0-2-95-101

Просмотров: 124


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)